Acumen Pharmaceuticals reported a reduced net loss for Q3 2025, with lower R&D and G&A expenses, and maintained a strong cash position to support its ongoing clinical programs.

Acumen Pharmaceuticals experienced a significant increase in net loss and loss from operations in Q2 2025, primarily driven by higher research and development expenses related to manufacturing and clinical trial activities for ALTITUDE-AD. Despite the financial losses, the company maintained a strong cash position, expected to fund operations into early 2027, and made progress in its clinical programs, including the ALTITUDE-AD Phase 2 study and a new Enhanced Brain Delivery (EBDTM) program.

Acumen Pharmaceuticals reported a net loss of $28.8 million for the first quarter of 2025, an increase from the prior year, primarily driven by higher research and development expenses related to their Phase 2 clinical trial. The company ended the quarter with $197.9 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into early 2027.

Acumen posted a $37.1M net loss in Q4 2024, driven by increased R&D spending on its ALTITUDE-AD trial. The company did not generate revenue and remains focused on its Alzheimer’s pipeline.

Acumen Pharmaceuticals reported a net loss of $29.8 million for the third quarter of 2024. As of September 30, 2024, cash, cash equivalents and marketable securities totaled $258.9 million, which is expected to support current clinical and operational activities into the first half of 2027.

Acumen Pharmaceuticals reported a net loss of $20.5 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $281.4 million as of June 30, 2024, which is expected to support operations into the first half of 2027. The company is actively enrolling subjects in ALTITUDE-AD, a Phase 2 study, and dosed the first subject in a Phase 1 study to support subcutaneous administration of sabirnetug in July 2024.

Acumen Pharmaceuticals reported a net loss of $14.9 million for the first quarter of 2024. As of March 31, 2024, cash, cash equivalents and marketable securities totaled $296.6 million, which is expected to support current clinical and operational activities into the first half of 2027.

Acumen Pharmaceuticals reported a net loss of $52.4 million for the year ended December 31, 2023. The company's cash, cash equivalents, and marketable securities totaled $306.1 million as of December 31, 2023, which is expected to support clinical and operational activities into the first half of 2027. The company is focused on advancing the clinical development of sabirnetug and expects to initiate a Phase 2 study in the first half of this year.

Acumen Pharmaceuticals reported a net loss of $13.0 million for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $282.7 million as of September 30, 2023, which is expected to support current clinical and operational activities into the second half of 2026.

Acumen Pharmaceuticals reported positive Phase 1 trial results for ACU193, demonstrating its potential for treating early Alzheimer's disease. They ended the quarter with $172.2 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2026. A Phase 2 study is expected to begin in the first half of 2024.

Acumen Pharmaceuticals reported a net loss of $11.3 million for the first quarter of 2023. As of March 31, 2023, cash, cash equivalents and marketable securities totaled $183.8 million.

Acumen Pharmaceuticals reported a net loss of $42.9 million for the year ended December 31, 2022, with cash, cash equivalents, and marketable securities totaling $193.4 million. The company completed enrollment in its Phase 1 INTERCEPT-AD trial and anticipates topline data in Q3 2023.

Acumen Pharmaceuticals reported a net loss of $10.7 million for the third quarter of 2022, compared to a net loss of $3.9 million for the same period in 2021. As of September 30, 2022, cash, cash equivalents and marketable securities totaled $200.2 million.

Acumen Pharmaceuticals reported $209.9 million in cash, cash equivalents and marketable securities as of June 30, 2022. R&D expenses were $7.3 million, and G&A expenses were $3.1 million for the three-month period ended June 30, 2022. The net loss was $10.2 million for the three-month period ended June 30, 2022.

Acumen Pharmaceuticals reported its financial results for Q1 2022, highlighting progress in its INTERCEPT-AD Phase 1 clinical trial and a cash balance of $216.7 million expected to fund operations through 2025.

Acumen Pharmaceuticals reported its full year 2021 financial results, highlighting progress with ACU193 clinical development and corporate team expansion. The company's cash, cash equivalents, and marketable securities totaled $225.9 million as of December 31, 2021, expected to fund operations through 2025.

Acumen Pharmaceuticals reported its Q3 2021 financial results, highlighting the closing of its initial public offering in July 2021 with net proceeds of $168.6 million and the enrollment of first patients in INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease. The company's cash and cash equivalents totaled $135.8 million, and marketable securities totaled $94.1 million as of September 30, 2021.

Acumen Pharmaceuticals reported a net loss of $61.4 million for the second quarter of 2021. The company's cash, cash equivalents, and marketable securities were $68.8 million as of June 30, 2021. Acumen closed its initial public offering in July 2021, with net proceeds of $169 million.